Apontis Pharma AG (APPH.DE)

EUR 11.15

(0.45%)

EBITDA Summary of Apontis Pharma AG

  • Apontis Pharma AG's latest annual EBITDA in 2023 was -12.94 Million EUR , down -332.75% from previous year.
  • Apontis Pharma AG's latest quarterly EBITDA in 2024 Q2 was 1.87 Million EUR , up 122.38% from previous quarter.
  • Apontis Pharma AG reported an annual EBITDA of 5.67 Million EUR in 2022, up 65.94% from previous year.
  • Apontis Pharma AG reported an annual EBITDA of 1.99 Million EUR in 2021, up 227.07% from previous year.
  • Apontis Pharma AG reported a quarterly EBITDA of -4.17 Million EUR for 2023 Q2, down -437.88% from previous quarter.
  • Apontis Pharma AG reported a quarterly EBITDA of -9.47 Million EUR for 2023 Q4, down -127.23% from previous quarter.

Annual EBITDA Chart of Apontis Pharma AG (2023 - 2019)

Historical Annual EBITDA of Apontis Pharma AG (2023 - 2019)

Year EBITDA EBITDA Growth
2023 -12.94 Million EUR -332.75%
2022 5.67 Million EUR 65.94%
2021 1.99 Million EUR 227.07%
2020 1.04 Million EUR 162.45%
2019 -1.67 Million EUR 0.0%

Peer EBITDA Comparison of Apontis Pharma AG

Name EBITDA EBITDA Difference
MPH Health Care AG 33.31 Million EUR 138.847%
Dermapharm Holding SE 277.29 Million EUR 104.667%
Evotec SE 7.82 Million EUR 265.427%
MERCK Kommanditgesellschaft auf Aktien 5.52 Billion EUR 100.234%
PharmaSGP Holding SE 35.86 Million EUR 136.08%
SynBiotic SE -7.12 Million EUR -81.694%